A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan.
Yao-Chi ChuangChih-Chieh LinPo-Ming ChowChi-Shun LienKe-Hung TsuiChieh-Lung ChouHsiang-Ying LeeEn MengHann-Chorng KuoPublished in: Lower urinary tract symptoms (2020)
Imidafenacin demonstrated efficacy and safety in the treatment of OAB in Taiwanese patients.
Keyphrases
- placebo controlled
- double blind
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- phase iii
- phase ii
- open label
- prognostic factors
- peritoneal dialysis
- clinical trial
- squamous cell carcinoma
- randomized controlled trial
- radiation therapy
- patient reported outcomes
- phase ii study
- combination therapy